How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,570 results for

Polypharmacy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Bad Medicine: Polypharmacy Full Text available with Trip Pro

Bad Medicine: Polypharmacy 29192108 2019 02 28 2019 02 28 1478-5242 67 665 2017 12 The British journal of general practice : the journal of the Royal College of General Practitioners Br J Gen Pract Bad Medicine: Polypharmacy. 562 10.3399/bjgp17X693737 Spence Des D Maryhill Health Centre, Glasgow. eng Journal Article England Br J Gen Pract 9005323 0960-1643 0 Prescription Drugs IM Br J Gen Pract. 2018 Feb;68(667):70 29371301 Drug Industry economics Health Care Costs Humans Polypharmacy Practice

2017 The British Journal of General Practice

182. “Dopamine homeostasis” requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America’s drug epidemic Full Text available with Trip Pro

“Dopamine homeostasis” requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America’s drug epidemic The well-researched pro-dopamine regulator KB220 and variants result in increased functional connectivity in both animal and human brains, and prolonged neuroplasticity (brain cell repair) having been observed in rodents. Moreover, in addition to increased functional connectivity, recent studies show that KB220Z increases overall brain connectivity

2017 Journal of systems and integrative neuroscience

183. Polypharmacy and potential drug–drug interactions in emergency department patients in the Caribbean Full Text available with Trip Pro

Polypharmacy and potential drug–drug interactions in emergency department patients in the Caribbean Background Potential Drug-Drug Interactions (DDI) account for many emergency department visits. Polypharmacy, as well as herbal, over-the-counter (OTC) and combination medication may compound this, but these problems are not well researched in low-and-middle-income countries. Objective To compare the incidence of drug-drug interactions and polypharmacy in older and younger patients attending (...) the Emergency Department (ED). Setting The adult ED of a tertiary teaching hospital in Trinidad. Methods A 4 month cross sectional study was conducted, comparing potential DDI in older and younger patients discharged from the ED, as defined using Micromedex 2.0. Main outcome measure The incidence and severity of DDI and polypharmacy (defined as the use of ≥5 drugs simultaneously) in older and younger patients attending the ED. Results 649 patients were included; 275 (42.3%) were ≥65 years and 381 (58.7

2017 International journal of clinical pharmacy

184. Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy Full Text available with Trip Pro

Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy This study investigates the antipsychotic use patterns of patients with schizophrenia and its correlations in their daily drug use patterns.Patients with schizophrenia who have regular records at two different community counselling centres (CCS) were included in the study. Information about their medications and sociodemographic data was recorded through face-to-face interviews and supporting information about (...) antipsychotic. Clinical severity, regular visits to a CCS and use of depot antipsychotics were independent predictors for polypharmacy.The rate of polypharmacy use is high in Turkey. There are multiple risk factors related with polipharmacy. New studies should focus risk factors for preventing polypharmacy.

2017 Clinical practice and epidemiology in mental health : CP & EMH

185. Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study Full Text available with Trip Pro

Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study To describe psychotropic polypharmacy in Australia between 2006 and 2015.We used pharmaceutical claims from a national 10% sample of people with complete dispensing histories to estimate the annual prevalence of the combined use (overlap of >60 days exposure) of ≥2 psychotropics overall and within the same class or subclass (class and subclass polypharmacy). We also estimated the proportion of polypharmacy episodes (...) involving one, two, three and four or more unique prescribers.The prevalence of class polypharmacy between 2006 and 2015 in people dispensed specific psychotropic classes was 5.9-7.3% for antipsychotics, 2.1-3.7% for antidepressants and 4.3-2.9% for benzodiazepines. The prevalence of antipsychotic polypharmacy was higher than expected given the prevalence of antipsychotic exposure and combinations of sedating agents were notably common. Overall, 26.7% of polypharmacy episodes involved multiple

2017 British journal of clinical pharmacology

186. Polypharmacy among Underserved Older African American Adults Full Text available with Trip Pro

Polypharmacy among Underserved Older African American Adults The purpose of the present study was to examine correlates of polypharmacy among underserved community-dwelling older African American adults. Methods. This study recruited 400 underserved older African Americans adults living in South Los Angeles. The structured face-to-face interviews collected data on participants' characteristics and elicited data pertaining to the type, frequency, dosage, and indications of all medications used (...) by participants. Results. Seventy-five and thirty percent of participants take at least five and ten medications per day, respectively. Thirty-eight percent of participants received prescription medications from at least three providers. Inappropriate drug use occurred among seventy percent of the participants. Multivariate analysis showed that number of providers was the strongest correlate of polypharmacy. Moreover, data show that gender, comorbidity, and potentially inappropriate medication use are other

2017 Journal of aging research

187. The polypharmacy challenge: time for a new script? Full Text available with Trip Pro

The polypharmacy challenge: time for a new script? 28860279 2018 07 09 2018 11 13 1478-5242 67 662 2017 09 The British journal of general practice : the journal of the Royal College of General Practitioners Br J Gen Pract The polypharmacy challenge: time for a new script? 388-389 10.3399/bjgp17X692189 Swinglehurst Deborah D Centre for Primary Care and Public Health, Blizard Institute, Queen Mary University of London, London. Fudge Nina N Centre for Primary Care and Public Health, Blizard (...) Institute, Queen Mary University of London, London. eng Editorial England Br J Gen Pract 9005323 0960-1643 IM Age Factors General Practice methods standards trends Humans Medication Therapy Management organization & administration standards Multimorbidity Polypharmacy Risk Factors United Kingdom 2017 9 2 6 0 2017 9 2 6 0 2018 7 10 6 0 ppublish 28860279 67/662/388 10.3399/bjgp17X692189 PMC5569714 Br J Gen Pract. 2017 Jul;67(660):e501-e506 28347987 BMJ Open. 2013 Sep 13;3(9):e003610 24038011 Br J Gen

2017 The British Journal of General Practice

188. Development of a core outcome set for medication review in older patients with multimorbidity and polypharmacy: a study protocol Full Text available with Trip Pro

Development of a core outcome set for medication review in older patients with multimorbidity and polypharmacy: a study protocol Medication review has been advocated to address the challenge of polypharmacy in older patients, yet there is no consensus on how best to evaluate its efficacy. Heterogeneity of outcomes reported in clinical trials can hinder the comparison of clinical trial findings in systematic reviews. Moreover, the outcomes that matter most to older patients might be under

2017 Clinical interventions in aging

189. Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients Full Text available with Trip Pro

Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients Reduced biodiversity and increased representation of opportunistic pathogens are typical features of gut microbiota composition in aging. Few studies have investigated their correlation with polypharmacy, multimorbidity and frailty. To assess it, we analyzed the fecal microbiota from 76 inpatients, aged 83 ± 8. Microbiome biodiversity (Chao1 index) and relative abundance of individual bacterial taxa were (...) was associated with the average relative abundance of 15 taxa. The drug classes exhibiting the strongest association with single taxa abundance were proton pump inhibitors, antidepressants and antipsychotics. Conversely, frailty and multimorbidity were not significantly associated with gut microbiota biodiversity. Very low Chao1 index was also a significant predictor of mortality, but not of rehospitalizations and sepsis, at follow-up. In aging, polypharmacy may thus represent a determinant of gut microbiota

2017 Scientific reports

190. Polypharmacy: a challenge for the primary health care of the Brazilian Unified Health System Full Text available with Trip Pro

Polypharmacy: a challenge for the primary health care of the Brazilian Unified Health System To characterize the polypharmacy in primary health care patients and to identify its associated factors.This is a cross-sectional, exploratory, and evaluative study, part of the Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos - Serviços, 2015 (PNAUM - National Survey on Access, Use and Promotion of Rational Use of Medicines - Services, 2015). The variable (...) of interest was polypharmacy, defined as the use of five or more medicines. We sought to identify the association of sociodemographic variables and indicators of health conditions to polypharmacy. For group comparison, the Pearson's Chi-square test was used. The association between polypharmacy and explanatory variables was evaluated by logistic regression model (p < 0.05). The quality of the adjustment was verified by Hosmer-Lemeshow test.The prevalence of polypharmacy among medicine users was 9.4% (95

2017 Revista de saúde pública

191. Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing Full Text available with Trip Pro

Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing The majority of patients respond to antipsychotic monotherapy at standard doses, but a subset of patients will require more heroic measures that include antipsychotic polypharmacy and high-dose monotherapy. Indeed, research has shown that roughly 30% of patients with psychosis are prescribed multiple antipsychotic medications. We discuss the potential benefits and challenges

2017 BJPsych bulletin

192. Clinician agreement and influence of medication‐related characteristics on assessment of polypharmacy Full Text available with Trip Pro

Clinician agreement and influence of medication‐related characteristics on assessment of polypharmacy It is not known how clinicians assess polypharmacy or the medication-related characteristics that influence their assessment. The aim of this study was to examine the level of agreement between clinicians when assessing polypharmacy and to identify medication-related characteristics that influence their assessment. Twenty cases of patients with varying levels of comorbidity and polypharmacy (...) were used to examine clinician assessment of polypharmacy. Medicine-related factors within the cases included Beers and STOPP Criteria medicines, falls-risk medicines, drug burden index (DBI) medicines, medicines causing postural hypotension, and pharmacokinetic drug-drug interactions. Clinicians were asked to rate cases on the degree of polypharmacy, likelihood of harm, and potential for the medication list to be simplified. Inter-rater reliability analysis, correlations, and multivariate logistic

2017 Pharmacology research & perspectives

193. Implementing an ICT-Based Polypharmacy Management Program in Italy Full Text available with Trip Pro

Implementing an ICT-Based Polypharmacy Management Program in Italy Although there is evidence of a growing awareness of the problem, no official policy statements or regulatory guidelines on polypharmacy have been released up to date by Italian Health Authorities. Medication review, application of appropriateness criteria and computerized prescription support systems are all possible approaches in order to improve the quality of prescribing in older persons. More focused training courses

2017 Translational medicine @ UniSa

194. Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus Full Text available with Trip Pro

Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus 28674868 2018 11 30 1619-1560 27 Suppl 1 2017 07 Clinical autonomic research : official journal of the Clinical Autonomic Research Society Clin. Auton. Res. Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus. 33-34 10.1007/s10286-017-0435-5 Vernino Steven S Department of Neurology

2017 Clinical Autonomic Research

195. Polypharmacy and Risk of Non-fatal Overdose for Patients with HIV Infection and Substance Dependence Full Text available with Trip Pro

Polypharmacy and Risk of Non-fatal Overdose for Patients with HIV Infection and Substance Dependence People living with HIV (PLWH) are at risk of both polypharmacy and unintentional overdose yet there are few data on whether polypharmacy increases risk of overdose. The study objective was to determine if the number and type of medication (e.g., sedating) were associated with non-fatal overdose (OD) among PLWH with past-year substance dependence or a lifetime history of injection drug use.This (...) opioid medication (OR 2.23; 95% CI 0.93, 5.35).In this sample of PLWH with substance dependence and/or injection drug use, number of sedating medications and any opioid were associated with non-fatal overdose; sedating medications were prescribed to the majority of patients. Polypharmacy among PLWH and substance dependence warrants further research to determine whether reducing sedating medications, including opioids, lowers overdose risk.Copyright © 2017 Elsevier Inc. All rights reserved.

2017 Journal of substance abuse treatment

196. A feasibility study of a theory-based intervention to improve appropriate polypharmacy for older people in primary care Full Text available with Trip Pro

A feasibility study of a theory-based intervention to improve appropriate polypharmacy for older people in primary care A general practitioner (GP)-targeted intervention aimed at improving the prescribing of appropriate polypharmacy for older people was previously developed using a systematic, theory-based approach based on the UK Medical Research Council's complex intervention framework. The primary intervention component comprised a video demonstration of a GP prescribing appropriate (...) polypharmacy during a consultation with an older patient. The video was delivered to GPs online and included feedback emphasising the positive outcomes of performing the behaviour. As a complementary intervention component, patients were invited to scheduled medication review consultations with GPs. This study aimed to test the feasibility of the intervention and study procedures (recruitment, data collection).GPs from two general practices were given access to the video, and reception staff scheduled

2017 Pilot and feasibility studies Controlled trial quality: uncertain

197. Prevalence and Geographic Variations of Polypharmacy Among West Virginia Medicaid Beneficiaries Full Text available with Trip Pro

Prevalence and Geographic Variations of Polypharmacy Among West Virginia Medicaid Beneficiaries West Virginia (WV) residents are at high risk for polypharmacy given its considerable chronic disease burdens.To evaluate the prevalence, correlates, outcomes, and geographic variations of polypharmacy among WV Medicaid beneficiaries.In this cross-sectional study, we analyzed 2009-2010 WV Medicaid fee-for-service (FFS) claims data for adults aged 18-64 (N=37,570). We defined polypharmacy (...) as simultaneous use of drugs from five or more different drug classes on a daily basis for at least 60 consecutive days in one year. Multilevel logistic regression was used to explore the individual- and county-level factors associated with polypharmacy. Its relationship with healthcare utilization was assessed using negative binomial regression and logistic regression. The univariate local indicators of spatial association method was applied to explore spatial patterns of polypharmacy in WV.The prevalence

2017 The Annals of pharmacotherapy

198. Trends in Central Nervous System–Active Polypharmacy Among Older Adults Seen in Outpatient Care in the United States Full Text available with Trip Pro

Trends in Central Nervous System–Active Polypharmacy Among Older Adults Seen in Outpatient Care in the United States 28192559 2018 10 22 2018 11 13 2168-6114 177 4 2017 04 01 JAMA internal medicine JAMA Intern Med Trends in Central Nervous System-Active Polypharmacy Among Older Adults Seen in Outpatient Care in the United States. 583-585 10.1001/jamainternmed.2016.9225 Maust Donovan T DT Department of Psychiatry, University of Michigan, Ann Arbor2Center for Clinical Management Research, VA (...) States Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States JAMA Intern Med 101589534 2168-6106 AIM IM Aged Aged, 80 and over Ambulatory Care Female Humans Male Mental Disorders drug therapy Pain drug therapy Polypharmacy United States 2017 2 14 6 0 2018 10 23 6 0 2017 2 14 6 0 ppublish 28192559 2601416 10.1001/jamainternmed.2016.9225 PMC5378654 NIHMS836615 J Clin Psychiatry. 2015 Jan;76(1):40-4 25188822 J Am Geriatr Soc. 2015 Nov;63(11):2227-46 26446832

2017 JAMA Internal Medicine

199. Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-Sectional Analysis Full Text available with Trip Pro

Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-Sectional Analysis A lack of gold standard treatment for autism spectrum disorders (ASD), no clear ASD management guidelines, and lack of evidence-based pharmacological interventions other than aripiprazole and risperidone elevate the risk of off-label prescribing and adverse effects among individuals with ASD, more so among adults.The aim of this study was to identify and compare the types (...) of prescription drug use, rates of polypharmacy, and characteristics associated with polypharmacy among adults with and without ASD in a retrospective cross-sectional analysis of a three-state Medicaid Analytic eXtract database (2000-2008).Adults aged 22-64 years with ASD (ICD9-CM code: 299.xx) were propensity score-matched to 'no ASD' controls by age, sex, and race. General polypharmacy (≥6 unique classes of prescription drugs in a year) and psychotropic polypharmacy (≥3 unique prescription drug classes

2016 Drugs - real world outcomes

200. Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal

Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal (DePil17-20) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03283735 Recruitment Status : Not yet recruiting First Posted

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>